HUL Acquires Full OZiva Stake, Sells Nutritionalab in Wellness Portfolio Shift

CONSUMER-PRODUCTS
Whalesbook Logo
AuthorAbhay Singh|Published at:
HUL Acquires Full OZiva Stake, Sells Nutritionalab in Wellness Portfolio Shift
Overview

Hindustan Unilever Limited is acquiring the remaining 49% stake in D2C health and wellness brand OZiva for ₹824 crore, making it a wholly-owned subsidiary. Concurrently, HUL is divesting its 19.8% stake in Nutritionalab for ₹307 crore. These moves strategically bolster HUL's presence in the high-growth Health & Wellbeing category, aligning with its 'fewer, bigger bets' strategy. OZiva has shown exceptional growth, scaling to approximately ₹480 crore from ₹257.67 crore in FY25, with a 130% CAGR over two years.

📉 The Financial Deep Dive

The Numbers: Hindustan Unilever Limited (HUL) has announced a significant portfolio realignment within its Health & Wellbeing (H&W) business. The company is set to acquire the remaining 49% stake in Zywie Ventures Private Limited (OZiva) for a cash consideration of ₹824 Crores, making it a wholly-owned entity. In a parallel move, HUL will divest its entire 19.8% shareholding in Nutritionalab Private Limited to USV Private Limited for ₹307 Crores. These transactions are expected to conclude by March 31, 2026.

The Quality: While specific profit and margin data for these transactions are not detailed, the strategic intent is clear. OZiva, which operates in the Health & Wellbeing, Vitamins, Minerals and Supplements, and Beauty and Personal Care sectors, reported a turnover of ₹257.67 Crores in FY2024-25. Post-HUL's initial investment, OZiva has demonstrated robust growth, scaling its business to approximately ₹480 Crores in 2025, driven by a remarkable 130% CAGR over the past two years. Nutritionalab, accounted for using the equity method, generated ₹118.48 Crores in turnover in FY2024-25, with its revenue not consolidated into HUL's results.

The Grill: Management, led by CEO and MD Priya Nair, articulated that the strategic rationale is to strengthen HUL's position in the Health & Wellbeing category, identified as a key growth vector. The full ownership of OZiva aims to unlock a new growth phase by leveraging HUL's strengths in science, distribution, and market development to scale purpose-led brands.

🚩 Risks & Outlook

Specific Risks: The primary risks revolve around the successful integration of OZiva into HUL's broader operational framework, ensuring the continuation of its agile D2C model while benefiting from HUL's scale. Regulatory approvals for the transactions and potential shifts in consumer demand within the dynamic health and wellness market are also key considerations. Execution risks in scaling the brand and maintaining its unique value proposition under a large conglomerate structure need careful management.

The Forward View: Investors will be watching how HUL capitalizes on OZiva's growth momentum. The 'fewer, bigger bets' strategy implies a sharper focus on scalable, purpose-driven brands. The market will expect HUL to demonstrate accelerated growth in its H&W segment, driven by this acquisition. The divestment of Nutritionalab signals a streamlining of the portfolio, prioritizing assets with clearer pathways to significant scale and impact.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.